J
Jazz Pharmaceuticals plc (JAZZ)
NMS – Real vaqt narxi. Valyuta: USD
182.69
-6.46 (-3.42%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
189.47
+6.78 (3.71%)
Bozordan keyin: Mar 27, 2026, 7:36 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NMS – Real vaqt narxi. Valyuta: USD
182.69
-6.46 (-3.42%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
189.47
+6.78 (3.71%)
Bozordan keyin: Mar 27, 2026, 7:36 PM EDT
Jazz Pharmaceuticals plc AQSh, Yevropa va xalqaro miqyosda farmatsevtika mahsulotlarini aniqlaydi, ishlab chiqadi va tijoratlashtiradi. Kompaniya narkolepsiya bilan bog'liq katapleksiya yoki haddan tashqari kunduzgi uyquchanlikni (EDS) va idiopatik giperinsomniyani (IH) davolash uchun Xywavni; Lennox-Gastaut sindromi (LGS), Dravet sindromi (DS) yoki tuberoz skleroz kompleksi (TSC) bilan bog'liq tirishmalarni davolash uchun Epidiolexni; o'tkir limfoblastik leykemiya yoki limfoblastik limfomani davolash uchun Rylazeni; o'tkir limfoblastik leykemiya va limfoblastik limfomani davolash uchun Enrylazeni; platina asosidagi kimyoterapiya paytida yoki undan keyin kasallikning rivojlanishi bilan metastatik mayda hujayrali o'pka rakini davolash uchun Zepzelcani; HER2-musbat o't yo'llari saratonini davolash uchun Ziiherani; H3 K27M mutatsiyasiga ega bo'lgan diffuz midline gliomasini davolash uchun Modeyso va og'ir veno-okkluziv kasallikni davolash uchun Defitelioni taklif etadi. Shuningdek, kompaniya HER2-musbat gastroezofagial adenokarsinoma (GEA) va o't yo'llari saratonini (BTC) davolash uchun 3-bosqichli sinovlarda Zanidatamabni; H3 K27M-mutatsiyalangan diffuz gliomani davolash uchun Dordavipronni va yangi tashxis qo'yilgan terapiya bilan bog'liq o'tkir miyeloid leykemiyani davolash uchun Vyxeosni ishlab chiqmoqda. Qo'shimcha ravishda, kompaniya ko'krak bezi rakini neoad'yuvant va adjuvant davolash uchun Zanidatamabni; yuqori xavfli MDS, yuqori xavfli AML bilan yangi tashxis qo'yilgan davolanmagan bemorlar va genomikaga qarab stratifikatsiyalangan yuqori xavfli AMLni davolash uchun Vyxeosni va fenoxromotsitoma va paragangliomani davolash uchun JZP3507ni ishlab chiqmoqda, ular 2-bosqichli klinik sinovlarda. Shuningdek, u Raf va Ras mutant o'smalarini davolash uchun JZP815ni; qattiq o'smalarda IFN INDUKIN molekulasi uchun JZP898ni va 1-bosqichli klinik sinovlarda bo'lgan absans epilepsiyani davolash uchun JZP047ni ishlab chiqmoqda. Kompaniya Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd. va Werewolf Therapeutics, Inc. bilan litsenziyalash va hamkorlik shartnomalariga ega. Jazz Pharmaceuticals plc 2003 yilda tashkil etilgan va uning shtab-kvartirasi Dublin, Irlandiyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jed Black M.D. | Senior Vice President of Sleep & CNS Medicine |
| Dr. Robert Iannone M.D. | Executive VP, Chief Medical Officer and Global Head of Research & Development |
| Jack W. Spinks | Executive Director of Investor Relations |
| Mr. Bruce C. Cozadd | Co-Founder & Chairman |
| Mr. Philip L. Johnson | Executive VP & CFO |
| Ms. Heidi Manna | Executive VP & Chief People Officer |
| Ms. Neena M. Patil J.D. | Executive VP & Chief Legal Officer |
| Ms. Patricia Carr | Senior VP & Chief Accounting Officer |
| Ms. Renee D. Gala | President, CEO & Director |
| Ms. Samantha Pearce | Executive VP & Chief Commercial Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-12 | 8-K | d61589d8k.htm |
| 2025-11-17 | 8-K | d827060d8k.htm |
| 2025-11-05 | 8-K | jazz-20251105.htm |
| 2025-10-28 | 8-K | jazz-20251023.htm |
| 2025-10-22 | 8-K | d65147d8k.htm |
| 2025-08-06 | 10-Q | jazz-20250630.htm |
| 2025-08-05 | 8-K | jazz-20250805.htm |
| 2025-07-29 | CORRESP | filename1.htm |
| 2025-07-25 | 8-K | jazz-20250724.htm |
| 2025-07-14 | DEFA14A | d927302ddefa14a.htm |